As COVID-19 infections in the U.S. hit new highs, President Joe Biden announced that the country would buy at least 20 million courses of Pfizer’s (NYSE:PFE) COVID-19 pill Paxlovid. The government had planned on purchasing half as much of the drug, which won regulatory authorization in late December for certain patients with a high risk of developing…
Pfizer bolsters COVID-19 antiviral manufacturing capacity
Although Pfizer (NYSE:PFE) has yet to receive emergency use authorization for its Paxlovid COVID-19 therapy, it plans to manufacture 80 million courses of the drug by the end of 2022. Pfizer had initially planned on making 50 million courses of Paxlovid (PF-07321332/ritonavir) in the same time frame. An interim analysis of the Phase 2/3 EPIC-HR…